Literature DB >> 26206305

Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.

Karen A Ryall1, Jimin Shin1, Minjae Yoo1, Trista K Hinz2, Jihye Kim1, Jaewoo Kang3, Lynn E Heasley1, Aik Choon Tan4.   

Abstract

MOTIVATION: Targeted kinase inhibitors have dramatically improved cancer treatment, but kinase dependency for an individual patient or cancer cell can be challenging to predict. Kinase dependency does not always correspond with gene expression and mutation status. High-throughput drug screens are powerful tools for determining kinase dependency, but drug polypharmacology can make results difficult to interpret.
RESULTS: We developed Kinase Addiction Ranker (KAR), an algorithm that integrates high-throughput drug screening data, comprehensive kinase inhibition data and gene expression profiles to identify kinase dependency in cancer cells. We applied KAR to predict kinase dependency of 21 lung cancer cell lines and 151 leukemia patient samples using published datasets. We experimentally validated KAR predictions of FGFR and MTOR dependence in lung cancer cell line H1581, showing synergistic reduction in proliferation after combining ponatinib and AZD8055.
AVAILABILITY AND IMPLEMENTATION: KAR can be downloaded as a Python function or a MATLAB script along with example inputs and outputs at: http://tanlab.ucdenver.edu/KAR/. CONTACT: aikchoon.tan@ucdenver.edu. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26206305      PMCID: PMC4675831          DOI: 10.1093/bioinformatics/btv427

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  37 in total

Review 1.  Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies.

Authors:  Chong Sun; René Bernards
Journal:  Trends Biochem Sci       Date:  2014-09-16       Impact factor: 13.807

2.  AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.

Authors:  Kwang Sup So; Jin Kyung Rho; Yun Jung Choi; Seon Ye Kim; Chang Min Choi; Young Jin Chun; Jae Cheol Lee
Journal:  Anticancer Res       Date:  2015-03       Impact factor: 2.480

Review 3.  Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.

Authors:  Claudia Fumarola; Mara A Bonelli; Pier Giorgio Petronini; Roberta R Alfieri
Journal:  Biochem Pharmacol       Date:  2014-05-24       Impact factor: 5.858

4.  Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

Authors:  Katherine R Singleton; Trista K Hinz; Emily K Kleczko; Lindsay A Marek; Jeff Kwak; Taylor Harp; Jihye Kim; Aik Choon Tan; Lynn E Heasley
Journal:  Cancer Res       Date:  2015-09-10       Impact factor: 12.701

Review 5.  Combinatorial drug therapy for cancer in the post-genomic era.

Authors:  Bissan Al-Lazikani; Udai Banerji; Paul Workman
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

6.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Authors:  Patrick P Zarrinkar; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Daniel Brigham; Barbara Belli; Mazen W Karaman; Keith W Pratz; Gabriel Pallares; Qi Chao; Kelly G Sprankle; Hitesh K Patel; Mark Levis; Robert C Armstrong; Joyce James; Shripad S Bhagwat
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

7.  Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Authors:  Jeffrey W Tyner; Wayne F Yang; Armand Bankhead; Guang Fan; Luke B Fletcher; Jade Bryant; Jason M Glover; Bill H Chang; Stephen E Spurgeon; William H Fleming; Tibor Kovacsovics; Jason R Gotlib; Stephen T Oh; Michael W Deininger; Christian Michel Zwaan; Monique L Den Boer; Marry M van den Heuvel-Eibrink; Thomas O'Hare; Brian J Druker; Marc M Loriaux
Journal:  Cancer Res       Date:  2012-10-18       Impact factor: 12.701

Review 8.  Targeted cancer therapy.

Authors:  Charles Sawyers
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

9.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971

10.  PubChem BioAssay: 2014 update.

Authors:  Yanli Wang; Tugba Suzek; Jian Zhang; Jiyao Wang; Siqian He; Tiejun Cheng; Benjamin A Shoemaker; Asta Gindulyte; Stephen H Bryant
Journal:  Nucleic Acids Res       Date:  2013-11-05       Impact factor: 16.971

View more
  8 in total

Review 1.  Exploiting receptor tyrosine kinase co-activation for cancer therapy.

Authors:  Aik-Choon Tan; Simon Vyse; Paul H Huang
Journal:  Drug Discov Today       Date:  2016-07-21       Impact factor: 7.851

2.  An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.

Authors:  Karen A Ryall; Jihye Kim; Peter J Klauck; Jimin Shin; Minjae Yoo; Anastasia Ionkina; Todd M Pitts; John J Tentler; Jennifer R Diamond; S Gail Eckhardt; Lynn E Heasley; Jaewoo Kang; Aik Choon Tan
Journal:  BMC Genomics       Date:  2015-12-09       Impact factor: 3.969

3.  Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles.

Authors:  Nadia Arang; Heather S Kain; Elizabeth K Glennon; Thomas Bello; Denali R Dudgeon; Emily N F Walter; Taranjit S Gujral; Alexis Kaushansky
Journal:  Nat Commun       Date:  2017-11-01       Impact factor: 14.919

4.  Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.

Authors:  Hong Sheng Cheng; Charlie Marvalim; Pengcheng Zhu; Cheng Lui Daniel Law; Zhi Yan Jeremy Low; Yuk Kien Chong; Beng Ti Ang; Carol Tang; Nguan Soon Tan
Journal:  Theranostics       Date:  2021-03-05       Impact factor: 11.556

5.  Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability.

Authors:  Edmund H Wilkes; Pedro Casado; Vinothini Rajeeve; Pedro R Cutillas
Journal:  Mol Cell Proteomics       Date:  2017-07-03       Impact factor: 5.911

6.  Progress towards a public chemogenomic set for protein kinases and a call for contributions.

Authors:  David H Drewry; Carrow I Wells; David M Andrews; Richard Angell; Hassan Al-Ali; Alison D Axtman; Stephen J Capuzzi; Jonathan M Elkins; Peter Ettmayer; Mathias Frederiksen; Opher Gileadi; Nathanael Gray; Alice Hooper; Stefan Knapp; Stefan Laufer; Ulrich Luecking; Michael Michaelides; Susanne Müller; Eugene Muratov; R Aldrin Denny; Kumar S Saikatendu; Daniel K Treiber; William J Zuercher; Timothy M Willson
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

Review 7.  Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance.

Authors:  Peter T Harrison; Paul H Huang
Journal:  Essays Biochem       Date:  2018-10-26       Impact factor: 8.000

Review 8.  Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress.

Authors:  Wei Xiang; Yi Hui Lam; Giridharan Periyasamy; Charles Chuah
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.